EN 简 繁

Collaboration

We maintain a dedicated and highly experienced business development team with strong expertise. Our business development strategy focuses on expanding and advancing our pipeline through both internal R&D and strategic external collaborations. A key example is our collaboration with BioNTech to develop and commercialize gotistobart. We intend to continue implementing this hybrid model of internal development and external partnerships to maximize the scientific, clinical, and commercial value of our programs.

Alliances and Partnerships

BioNTech (Nasdaq: BNTX)

We entered into an exclusive worldwide license and collaboration agreement with BioNTech to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, as monotherapy or combination therapy in various cancer indications.

Merck (NYSE: MRK)

We entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc. (known as MSD outside the United States and Canada) to evaluate gotistobart in combination with pembrolizumab (KEYTRUDA®), Merck’s anti–PD-1 therapy, in clinical trials.